Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is a leader in the multi-cancer early detection market, with their innovative blood test having the potential to detect all types of cancer at all stages. Despite a strong Q1 performance and positive expectations for upcoming catalysts such as ASCO data and FDA approval, ASP compression and uncertainties around Medicare reimbursement present potential risks. However, with a favorable risk/reward profile and a strong potential for future growth, GRAIL remains a buy rated stock.

Bears say

GRAIL is a company focused on multi-cancer early detection, which may be a strong concept, but its shares hold a neutral outlook, with a projected 2027 revenue of 40.6M diluted shares and only targeting 450 major health systems for adoption. Additionally, its lack of seamless EMR integration and reliance on the consumer self-pay market until FDA approval may pose challenges in the clinic and hinder its growth potential.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.